KLK3 and prostate cancer: The methodology used was previously described in a pilot study showing that the differences in terms of plasmatic levels of Exo-PSA between cancer patients and controls were consistent with the release of Exo-PSA between human prostate cancer cells cultured at different pH conditions [14]; the previous study set up all the methodologies exploited in this clinical investigation.